drugset / Trial / NCT04727073
Spironolactone in the Treatment of Heart Failure
Phase 3
Terminated
743 enrolled
Charite University, Berlin, Germany
Coordinating Centre for Clinical Trials, Charité · collabDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) · collabEcho Core Lab Berlin · collabInstitute for Cardiovascular Computer-assisted Medicine, Charité · collabLudwig-Maximilians - University of Munich · collabUniversity Medicine Greifswald · collabUniversity of Göttingen · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine whether the treatment of patients with HFmrEF and HFpEF at high risk of cardiovascular events with the mineralocorticoid receptor antagonist (MRA) spironolactone reduces a composite of recurrent heart failure hospitalizations and cardiovascular mortality.
Timeline
- Start
- 2018-11-01
- Primary completion
- 2024-10-01
- Completion
- 2024-10-01
Outcome
Outcome not reported
Stopped (Enrollment): “No extension of study funding by the DZHK following COVID-19 pandemic-induced prolongation of the recruitment period, also requiring manufacturing of further study drug batches”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Spironolactone | Small molecule | 50 mg | Oral |